A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Inclusion Criteria: All subjects must meet the following criteria for inclusion: * ≥ 18 years of age * Life expectancy of ≥ 3 months * Histological or cytological evidence of advanced and/or metastatic carcinoma or melanoma , excluding sarcoma * At least 1 measurable disease lesion as defined by RECIST 1.1 * Serum creatinine clearance ≥ 60 mL/min and serum creatinine ≤ 2.0 x the upper limit of normal (ULN) as determined by either of the following: Estimation as calculated by Cockcroft-Gault equation or Direct measurement by 24-hour urine collection * Total bilirubin ≤ 1.5 x ULN (unless elevated due to Gilbert's syndrome) * Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 2.5 x ULN (\<5x ULN if liver metastasis) * Adequate hematological function, defined as absolute neutrophil count ≥1.5 x 109/L, hemoglobin ≥ 9.0 g/dL, and platelet count ≥ 100 x 109/L * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (corresponds to Karnofsky Performance Status (KPS) ≥ 60%) Subjects entering Part A, B, C, or D must also meet the following additional criterion: • Failure to respond to standard therapy, or for whom no appropriate therapies are available (based on the judgement of the Investigator) Subjects entering Part D, E, F or G must also meet the following additional criterion: • Willing to undergo 1 pre-treatment and 1 on-treatment tumor biopsy Subjects entering Part E must also meet the following additional criteria: * Histological o…